Search: L773:1873 4898 OR L773:1477 5131
> (2006-2009) >
Treatment of vesico...
Treatment of vesicoureteral reflux in children using stabilized non-animal hyaluronic acid/dextranomer gel (NASHA/DX) : A long-term observational study
-
- Stenberg, Arne (author)
- Uppsala universitet,Institutionen för kvinnors och barns hälsa,Barnkirurgi/Christofferson
-
- Läckgren, Göran (author)
- Uppsala universitet,Institutionen för kvinnors och barns hälsa,Barnkirurgi/Christofferson
-
(creator_code:org_t)
- Elsevier BV, 2007
- 2007
- English.
-
In: Journal of Pediatric Urology. - : Elsevier BV. - 1477-5131. ; 3:2, s. 80-85
- Related links:
-
https://urn.kb.se/re...
-
show more...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- OBJECTIVE: Vesicoureteral reflux (VUR) can be treated with open surgery, antibiotic therapy or endoscopic injection. A goal in children is to reduce the incidence of febrile urinary tract infections (UTIs). The present long-term observational study investigated outcomes and experiences of endoscopic treatment with stabilized non-animal hyaluronic acid/dextranomer, NASHAtrade mark/Dx. PATIENTS AND METHODS: Children treated with NASHA/Dx between 1993 and 1998 were sent a questionnaire by mail in 2005. Patients included in the study (n=231) had VUR grade III-V before treatment and grade 0-II afterwards. Patients completed 21 questions, with parental assistance if required. The questionnaire assessed clinical outcome, and the attitudes of both patients and their parents to their experiences of treatment with NASHA/Dx gel. Patients reporting UTI after treatment were contacted and their records analyzed. RESULTS: Questionnaires were completed by 179 eligible patients. Most (72%) received a single injection of NASHA/Dx gel, and all experienced febrile UTI before treatment. After treatment, 45 patients (25%) experienced UTI; 25 of these reported fever. Patient records and telephone interviews revealed no evidence of febrile UTI in 19 cases; febrile UTI was confirmed in six cases, an incidence of 3.4%. When asked about the worst aspect of VUR treatment, 9% indicated treatment with NASHA/Dx compared to 19% for medication and 72% for voiding cystourethrogram (VCUG); parent-rated responses were 19%, 24% and 57%, respectively. CONCLUSIONS: Endoscopic treatment with NASHA/Dx gel was associated with a low number of febrile UTIs following treatment, viewed positively and considered less bothersome than medication or VCUG. These findings support this treatment as a primary intervention for VUR.
Keyword
- Vesicoureteral reflux
- Children
- NASHA/Dx
- Follow-up
- Endoscopic injection
- MEDICINE
- MEDICIN
- Kirurgi, särskilt urologi
- Urology
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database